Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Epitestosterone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | SHBG | P04278 | 5/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 3/20 | 1.00 |
| ▸ | PGR | P06401 | 3/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 3/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | SNCA | P37840 | 2/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 2/20 | 1.00 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 1.00 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.73 |
| ▸ | ESR1 | P03372 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epitestosterone SCHEMBL14007478 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL13988208 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Testosterone SCHEMBL15756675 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL13988209 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Testosterone SCHEMBL8452 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL11169161 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL13988894 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL21957465 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL22704809 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 | |
| Epitestosterone SCHEMBL334193 | 1.00 | AR (1.00) | ARLMNACYP3A4SHBGCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110643667-B | Biological dehydrogenation method of methyltestosterone C1,2 position | 湖南新合新生物医药有限公司 | 2023-05-05 | — | — | CN | claimed |
| WO-2016033556-A1 | BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS | LIPOCINE INC. (US) | 2016-03-03 | — | — | WO | claimed |
| WO-2002092618-A1 | 17 ALPHA-HYDROXY-4-ANDROSTENE-3-ONE AND THE 14, 15-METHYLENE-DERIVATIVES THEREOF | SCHERING AG (DE) | 2002-11-21 | — | — | WO | claimed |
| CN-110643667-B | Biological dehydrogenation method of methyltestosterone C1,2 position | 湖南新合新生物医药有限公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115052975-A | P450 BM3 monooxygenase variants for C19-hydroxylation of steroids | 拜耳公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-112852767-B | Carbonyl reductase mutant and application thereof in catalytic synthesis of 17 beta-hydroxy steroid compound | 中国科学院天津工业生物技术研究所 | 2022-04-05 | — | — | CN | disclosed |
| WO-2021156043-A1 | TESTOSTERONE CONTAINING PHARMACEUTICAL COMPOSITION | DIURNAL LIMITED (GB) | 2021-08-12 | — | — | WO | disclosed |
| US-20210199646-A1 | SAMPLE DEPLETION AND ENRICHMENT TO IMPROVE THE QUALITY OF DIAGNOSTIC TEST RESULTS | VERAVAS, INC. | 2021-07-01 | — | — | US | disclosed |
| WO-2021097182-A1 | TESTOSTERONE COMPOSITIONS | GLIA, LLC (US) | 2021-05-20 | — | — | WO | disclosed |
| EP-2706985-B1 | INTRANASAL LOWER DOSAGE STRENGTH TESTOSTERONE GEL FORMULATIONS AND USE THEREOF FOR TREATING ANORGASMIA OR HYPOACTIVE SEXUAL DESIRE DISORDER | ACERUS BIOPHARMA INC (CA) | 2020-07-22 | — | — | EP | disclosed |
| CN-111386119-A | Powder nasal administration preparation | ASKA制药株式会社 | 2020-07-07 | — | — | CN | disclosed |
| EP-0783512-A4 | NOVEL ANDROSTANES FOR INDUCING HYPOTHALAMIC EFFECTS | PHERIN CORP (US) | 1998-09-02 | — | — | EP | disclosed |
| EP-0783512-A1 | NOVEL ANDROSTANES FOR INDUCING HYPOTHALAMIC EFFECTS | PHERIN CORPORATION (US) | 1997-07-16 | — | — | EP | disclosed |
| EP-0711169-A1 | ANDROSTANE STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN HYPOTHALAMIC FUNCTION AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS | PHERIN CORPORATION (US) | 1996-05-15 | — | — | EP | disclosed |
| WO-1996010031-A1 | NOVEL ANDROSTANES FOR INDUCING HYPOTHALAMIC EFFECTS | PHERIN CORPORATION (US) | 1996-04-04 | — | — | WO | disclosed |
| EP-0655136-A1 | HAPTEN ASSAY DEVICE AND USE THEREOF | BIO MERIEUX (FR) | 1995-05-31 | — | — | EP | disclosed |
| WO-1994029723-A1 | HAPTEN ASSAY DEVICE AND USE THEREOF | BIO MERIEUX (FR) | 1994-12-22 | — | — | WO | disclosed |
| WO-1994028904-A1 | ANDROSTANE STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN HYPOTHALAMIC FUNCTION AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS | PHERIN CORPORATION (US) | 1994-12-22 | — | — | WO | disclosed |
| US-4181669-A | A CARBODIIMIDE WITH ACID CATALYSTS AS A CONDENSATION AGENT | AKTIEBOLAGET LEO (SE) | 1980-01-01 | — | — | US | disclosed |
| US-4180504-A | Method for the preparation of esters | AKTIEBOLAGET LEO (SE) | 1979-12-25 | — | — | US | disclosed |